Liquidity ratios measure the company ability to meet its short-term obligations.
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Common-Size Income Statement
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Common Stock Valuation Ratios
- Operating Profit Margin since 2005
- Debt to Equity since 2005
- Price to Earnings (P/E) since 2005
- Analysis of Revenues
- Analysis of Debt
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Liquidity Ratios (Summary)
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
- Current Ratio
-
The current ratio demonstrated an overall increasing trend from March 2020, beginning at 3.54 and reaching a peak of 4.83 by December 2022. This reflects an improvement in the company's short-term liquidity position over this period. Subsequently, the ratio showed a gradual decline, tapering off to 2.65 by March 2025. The earlier stability and increase suggest strong working capital maintenance, while the later decrease could indicate a reduction in current assets relative to current liabilities or potentially increased current liabilities.
- Quick Ratio
-
The quick ratio mirrored the general pattern observed in the current ratio, rising steadily from 3.27 in March 2020 to a high of 4.46 in December 2022, accompanied by minor fluctuations. After this peak, it steadily declined to approximately 2.12 by March 2025. The strong initial increase suggests an improvement in liquid assets excluding inventories, while the subsequent reduction may point to a decrease in readily available liquid assets or an increase in short-term liabilities.
- Cash Ratio
-
The cash ratio also followed a similar trajectory, increasing from 2.72 in March 2020 to a maximum of 3.93 in December 2022. This indicates an enhancement of the company's cash and cash equivalents in relation to current liabilities over this timeframe. Afterward, the ratio declined more sharply compared to the current and quick ratios, reaching 1.64 by March 2025. The sharper decrease in the cash ratio suggests a relatively larger reduction in cash reserves or cash equivalents compared to other liquid assets or an increase in current liabilities.
Current Ratio
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
Current assets | ||||||||||||||||||||||||||||
Current liabilities | ||||||||||||||||||||||||||||
Liquidity Ratio | ||||||||||||||||||||||||||||
Current ratio1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Current Ratio, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
- Current Assets
- The current assets demonstrate an overall increasing trend from March 31, 2020, to December 31, 2023, peaking around 14,695,800 thousand US dollars. After this peak, the values decline notably into 2024, reaching approximately 8,941,600 thousand US dollars by June 30, 2024. Subsequently, a modest recovery is observed, with a rise to roughly 10,008,800 thousand US dollars by March 31, 2025. This pattern suggests strong asset accumulation until late 2023, followed by a significant reduction and partial rebound in the following quarters.
- Current Liabilities
- An upward trend in current liabilities is observed from March 31, 2020, starting at roughly 1,538,750 thousand US dollars and increasing steadily to a high near 3,599,400 thousand US dollars by September 30, 2023. Afterward, the liabilities fluctuate moderately, with values between approximately 3,546,000 and 3,993,100 thousand US dollars through early 2025. This indicates a growth in short-term obligations correlating with the rise in current assets during the period, followed by stabilization at elevated levels.
- Current Ratio
- The current ratio shows a generally strong liquidity position over the timeline, starting at 3.54 in March 2020 and improving to a peak around 4.83 by December 2022. However, from that peak forward, the ratio declines consistently through 2023 and into 2024, reaching lows near 2.47 by September 2024. A slight uptick to 2.65 is noted by March 2025. Although the ratio remains above 2.0, indicating adequate liquidity, the downward trend after 2022 reflects a relative decrease in current assets compared to liabilities, suggesting caution regarding short-term financial stability.
- Summary of Trends
- The data reflects a period of asset growth outpacing liabilities until late 2023, resulting in a high current ratio and strong liquidity. Post-2023, a notable drop in current assets coupled with sustained current liabilities contributes to a declining current ratio. The partial recovery in assets toward early 2025 may indicate efforts to rebalance liquidity. Overall, the financial position shows robust liquidity with emerging signs of tighter short-term asset coverage relative to liabilities in recent quarters.
Quick Ratio
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
Cash and cash equivalents | ||||||||||||||||||||||||||||
Marketable securities | ||||||||||||||||||||||||||||
Accounts receivable, net | ||||||||||||||||||||||||||||
Total quick assets | ||||||||||||||||||||||||||||
Current liabilities | ||||||||||||||||||||||||||||
Liquidity Ratio | ||||||||||||||||||||||||||||
Quick ratio1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Quick Ratio, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The financial data reveals notable trends in liquidity and short-term financial health as reflected by total quick assets, current liabilities, and the quick ratio over multiple quarterly periods.
- Total Quick Assets
- Total quick assets demonstrate an overall increasing trend from March 31, 2020 (approximately $5.04 billion) through December 31, 2023 (approximately $12.8 billion), indicating a strong accumulation of liquid assets available to meet short-term obligations. However, from December 31, 2023 onward, there is a marked decrease in quick assets, falling sharply to $7.45 billion by June 30, 2024, before exhibiting some volatility and a partial recovery to about $8.0 billion by March 31, 2025. This decline after December 2023 suggests a reduction in readily available liquid assets, possibly due to increased spending or conversion of assets into less liquid forms.
- Current Liabilities
- Current liabilities generally trend upwards over the observed period. Starting at approximately $1.54 billion in March 2020, liabilities increase steadily to roughly $3.54 billion by December 2023, indicating a rising level of short-term obligations. Following December 2023, liabilities remain elevated with fluctuations, peaking near $3.97 billion in September 2024 and standing at approximately $3.78 billion by March 2025. The growth in current liabilities suggests increased operational or financing obligations occurring over time.
- Quick Ratio
- The quick ratio, a measure of short-term liquidity calculated as quick assets divided by current liabilities, starts above 3.2 in March 2020 and generally rises, reaching a peak above 4.4 by December 2022, signifying very strong liquidity. However, from early 2023 onward, the ratio declines steadily, falling below 4.0 by March 2023 and continuing down through 2024 to values slightly above 2.0 by late 2024 and early 2025. This downward trend reflects that quick asset growth has not kept pace with the rise in current liabilities, implying a weakening in liquidity position. Despite this decline, the quick ratio values remain above 2.0, still indicating a comfortable ability to cover short-term liabilities with liquid assets.
In summary, while the company established a robust liquidity position through 2022, significant changes beginning in late 2023 have led to decreased liquid asset levels and rising current liabilities, culminating in a reduced quick ratio. This shift may warrant further investigation into the causes of increased liabilities and decreased liquid assets, as well as the sustainability of the current liquidity levels moving forward.
Cash Ratio
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||||
Cash and cash equivalents | ||||||||||||||||||||||||||||
Marketable securities | ||||||||||||||||||||||||||||
Total cash assets | ||||||||||||||||||||||||||||
Current liabilities | ||||||||||||||||||||||||||||
Liquidity Ratio | ||||||||||||||||||||||||||||
Cash ratio1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Cash Ratio, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
- Total Cash Assets
-
The total cash assets exhibited a generally upward trend from March 31, 2020, to December 31, 2023, increasing from approximately $4.19 billion to around $11.93 billion. This reflects a substantial accumulation of liquidity over this period. However, starting in March 31, 2024, the cash assets experienced a sharp decline, falling to about $5.80 billion by June 30, 2024. A modest recovery occurred in the following quarters, with cash assets fluctuating around $6.1 to $6.2 billion up to March 31, 2025. Overall, the data show strong liquidity growth for nearly four years followed by a marked contraction in cash reserves.
- Current Liabilities
-
Current liabilities generally increased throughout the observation period. Beginning at roughly $1.54 billion in March 31, 2020, liabilities rose gradually, reaching $3.60 billion by December 31, 2023. Following this peak, a slight fluctuation was observed, with liabilities stabilizing around $3.54 to $3.79 billion during 2024 and early 2025. This upward trend in current liabilities indicates growing short-term obligations, which may impact working capital and liquidity management strategies.
- Cash Ratio
-
The cash ratio stayed above 2.5 from early 2020 through the end of 2023, peaking near 3.93 at the end of 2022 and maintaining relatively strong coverage of current liabilities by cash assets. Beginning in 2024, the ratio declined sharply to approximately 1.63 by June 30, 2024, and remained near this lower level through March 31, 2025. This significant drop in the cash ratio reflects diminished liquidity relative to current liabilities, likely due to the simultaneous decrease in cash assets and sustained or increased short-term obligations.
- Overall Insights
-
The financial data suggest a period of robust liquidity growth through most of 2020 to 2023, demonstrated by rising cash reserves and a strong cash ratio comfortably above 3. This indicates conservative liquidity management and a strong cash position relative to current liabilities. However, 2024 marks a turning point with a pronounced decrease in cash assets alongside continued high levels of current liabilities. Consequently, the cash ratio deteriorated markedly, which may signal increasing liquidity risk or increased cash outflows possibly linked to operational needs, investment activities, or strategic expenditures.
The persistence of elevated current liabilities combined with a reduced cash ratio warrants close monitoring of liquidity to ensure ongoing capability to meet short-term obligations. Strategic attention may be required to manage or restructure short-term liabilities or to improve cash generation to restore healthier liquidity metrics.